Furosemide
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Furosemide
- Generic name
- FUROSEMIDE
- Manufacturer
- Medical Purchasing Solutions, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- ea4ead7c-c798-2d85-e053-2a95a90ab0b0
- SPL ID
- fa1d9225-c7df-8f44-e053-6394a90a3984
- Version
- 4
- Effective date
- 2023-04-24
- Source export date
- 2026-09-28
- Source partition
- 9
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0009-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/6784607726c827491ceaeab30d843632e0660ee8008c535197be5ed9e1e52201/drug-label-0009-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:03:33
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 203428 | derived:openfda.application_number |
| application number | ANDA203428 | openfda.application_number | |
| brand name | Furosemide | openfda.brand_name | |
| generic name | FUROSEMIDE | openfda.generic_name | |
| manufacturer name | Medical Purchasing Solutions, LLC | openfda.manufacturer_name | |
| ndc | package | 71872-7295-1 | openfda.package_ndc |
| ndc | product | 71872-7295 | openfda.product_ndc |
| ndc11 | package | 71872729501 | derived:openfda.package_ndc |
| rxcui | 1719290 | openfda.rxcui | |
| spl id | fa1d9225-c7df-8f44-e053-6394a90a3984 | id | |
| spl set id | ea4ead7c-c798-2d85-e053-2a95a90ab0b0 | set_id | |
| unii | 7LXU5N7ZO5 | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient's needs. (See DOSAGE AND ADMINISTRATION .)
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings
WARNINGS In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma; therefore, strict observation is necessary during the period of diuresis. Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing hypokalemia and metabolic alkalosis. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued. Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used). (See PRECAUTIONS, Drug Interactions . ) Pediatric Use: In premature neonates with respiratory distress syndrome, diuretic treatment with furosemide in the first few weeks of life may increase the risk of persistent patent ductus arteriosus (PDA), possibly through a prostaglandin-E-mediated process. Literature reports indicate that premature infants with post conceptual age (gestational plus postnatal) less than 31 weeks receiving doses exceeding 1 mg/kg/24 hours may develop plasma levels which could be associated with potential toxic effects including ototoxicity. Hearing loss in neonates has been associated with the use of furosemide injection (see WARNINGS , above).
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Adverse reactions are categorized below by organ system and listed by decreasing severity. Gastrointestinal System Reactions 1. Hepatic encephalopathy in patients with hepatocellular insufficiency 6. Oral and gastric irritation 7. Cramping 2. Pancreatitis 8. Diarrhea 3. Jaundice (intrahepatic cholestatic jaundice) 9. Constipation 4. Increased liver enzymes 10. Nausea 5. Anorexia 11. Vomiting Systemic Hypersensitivity Reactions 1. Severe anaphylactic or anaphylactoid reactions (e.g. with shock) 3. Interstitial nephritis 4. Necrotizing angiitis 2. Systemic vasculitis Central Nervous System Reactions 1. Tinnitus and hearing loss 5. Headache 2. Paresthesias 6. Blurred vision 3. Vertigo 7. Xanthopsia 4. Dizziness Hematologic Reactions 1. Aplastic anemia 5. Leukopenia 2. Thrombocytopenia 6. Anemia 3. Agranulocytosis 7. Eosinophilia 4. Hemolytic anemia Dermatologic-Hypersensitivity Reactions 1. Exfoliative dermatitis 6. Urticaria 2. Bullous pemphigoid 7. Rash 3. Erythema multiforme 8. Pruritus 4. Purpura 9. Stevens-Johnson Syndrome 5. Photosensitivity 10. Toxic epidermal necrolysis Cardiovascular Reaction 1. Orthostatic hypotension may occur and be aggravated by alcohol, barbiturates or narcotics. 2. Increase in cholesterol and triglyceride serum levels. Other Reactions 1. Hyperglycemia 7. Urinary bladder spasm 2. Glycosuria 8. Thrombophlebitis 3. Hyperuricemia 4. Muscle spasms 9. Transient injection site pain following intramuscular injection 5. Weakness 10. Fever 6. Restlessness Whenever adverse reactions are moderate or severe, furosemide dosage should be reduced or therapy withdrawn.
adverse reactions table
<table ID="ID36" width="100%"><col width="50%"/><col width="50%"/><tbody><tr><td colspan="2" align="center" styleCode="Lrule Toprule Botrule Rrule Toprule" valign="top"><content styleCode="bold"> Gastrointestinal System Reactions</content> </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 1. Hepatic encephalopathy in patients with hepatocellular insufficiency </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 6. Oral and gastric irritation 7. Cramping </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 2. Pancreatitis </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 8. Diarrhea </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 3. Jaundice (intrahepatic cholestatic jaundice) </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 9. Constipation </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 4. Increased liver enzymes </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 10. Nausea </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 5. Anorexia </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 11. Vomiting </td></tr><tr><td colspan="2" align="left" styleCode="Lrule Botrule Rrule" valign="top"><content styleCode="bold"> Systemic Hypersensitivity Reactions</content> </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 1. Severe anaphylactic or anaphylactoid reactions (e.g. with shock) </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 3. Interstitial nephritis 4. Necrotizing angiitis </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 2. Systemic vasculitis </td><td styleCode=" Botrule Rrule" valign="top"/></tr><tr><td colspan="2" align="center" styleCode="Lrule Botrule Rrule" valign="top"><content styleCode="bold"> Central Nervous System Reactions</content> </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 1. Tinnitus and hearing loss </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 5. Headache </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 2. Paresthesias </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 6. Blurred vision </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 3. Vertigo </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 7. Xanthopsia </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 4. Dizziness </td><td styleCode=" Botrule Rrule" valign="top"/></tr><tr><td colspan="2" align="center" styleCode="Lrule Botrule Rrule" valign="top"><content styleCode="bold"> Hematologic Reactions</content> </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 1. Aplastic anemia </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 5. Leukopenia </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 2. Thrombocytopenia </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 6. Anemia </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 3. Agranulocytosis </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 7. Eosinophilia </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 4. Hemolytic anemia </td><td styleCode=" Botrule Rrule" valign="top"/></tr><tr><td colspan="2" align="center" styleCode="Lrule Botrule Rrule" valign="top"><content styleCode="bold"> Dermatologic-Hypersensitivity Reactions</content> </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 1. Exfoliative dermatitis </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 6. Urticaria </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 2. Bullous pemphigoid </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 7. Rash </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 3. Erythema multiforme </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 8. Pruritus </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 4. Purpura </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 9. Stevens-Johnson Syndrome </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 5. Photosensitivity </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 10. Toxic epidermal necrolysis </td></tr><tr><td colspan="2" align="left" styleCode="Lrule Botrule Rrule" valign="top"><content styleCode="bold"> Cardiovascular Reaction</content> </td></tr><tr><td colspan="2" align="left" styleCode="Lrule Botrule Rrule" valign="top"> 1. Orthostatic hypotension may occur and be aggravated by alcohol, barbiturates or narcotics. 2. Increase in cholesterol and triglyceride serum levels. </td></tr><tr><td colspan="2" align="left" styleCode="Lrule Botrule Rrule" valign="top"><content styleCode="bold"> Other Reactions</content> </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 1. Hyperglycemia </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 7. Urinary bladder spasm </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 2. Glycosuria </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 8. Thrombophlebitis </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 3. Hyperuricemia 4. Muscle spasms </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 9. Transient injection site pain following intramuscular injection </td></tr><tr><td align="left" styleCode="Lrule Botrule Rrule" valign="top"> 5. Weakness </td><td align="left" styleCode=" Botrule Rrule" valign="top"> 10. Fever </td></tr><tr><td align="left" styleCode=" Lrule Botrule Rrule" valign="top"> 6. Restlessness </td><td styleCode=" Botrule Rrule" valign="top"/></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.